As expected, teriparatide failed to show significant effects on bone erosion of the hands or wrists in RA patients treated with TNF inhibitors and not taking other osteoporosis treatment [88]; these results were subsequently confirmed by Ebina et al. [81], who showed a positive effect on the prevention of bone erosions only when oral bisphosphonates were switched to denosumab in patients with RA, and not if they were continued or switched to daily teriparatide. Here, TNF is linked to rheumatoid arthritis.